Fedratinib 治疗芦可替尼经治骨髓纤维化:JAKARTA2 研究严格失败标准的更新分析
JAKARTA2 Ⅱ期研究更新分析采用意向性治疗原则(无 LOCF),评估 Fedratinib 400 mg/日在芦可替尼耐药或不耐受的中高危骨髓纤维化患者中的疗效。全部治疗患者(N=97)脾脏体积应答率为31%,严格标准亚组(n=79)为30%,症状应答率27%,≥3级贫血和血小板减少分别为38%和22%。
要点
- 芦可替尼经治骨髓纤维化患者中,Fedratinib 脾脏应答率约30%
- 症状应答率27%,脾脏应答持续时间未达到
- ≥3级贫血38%、血小板减少22%,需关注血液学毒性
核心结论
- 对芦可替尼经治的中高危骨髓纤维化患者,Fedratinib 仍可获得稳健的脾脏应答并减轻症状负担。
研究设计与样本
- Ⅱ期 JAKARTA2 研究更新分析,采用意向性治疗原则且不使用 LOCF,全部治疗患者 N=97。
- 严格标准亚组 n=79,患者符合更严格的既往芦可替尼失败定义。
- Fedratinib 400 mg/日,28天为一周期;既往芦可替尼暴露中位时间10.7个月。
主要发现
- 主要终点脾脏体积应答率(从基线至第6周期末下降≥35%)在 ITT 人群为31%,严格标准亚组为30%。
- 脾脏体积应答中位持续时间未达到。
- 症状应答率(改良 MFSAF 总症状评分从基线至第6周期末下降≥50%)为27%。
- ≥3级贫血发生率为38%,≥3级血小板减少发生率为22%。
关键数值与推荐
- 脾脏体积应答定义:从基线至第6周期末脾脏体积下降≥35%。
- 症状应答定义:改良 MFSAF 总症状评分从基线至第6周期末下降≥50%。
临床怎么用
- 对芦可替尼耐药或不耐受的中高危骨髓纤维化患者,可考虑 Fedratinib 400 mg/日治疗。
- 治疗中需监测贫血和血小板减少等血液学毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate- or high-risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day in 28-day cycles. The JAKARTA2 outcomes were initially reported using a last-observation-carried forward (LOCF) analysis in a "Per Protocol" population. This updated analysis of JAKARTA2 employs intention-to-treat analysis principles without LOCF for all treated patients (ITT Population; N = 97), and for a patient subgroup who met more stringent definitions of prior ruxolitinib failure (Stringent Criteria Cohort; n = 79). Median duration of prior ruxolitinib exposure was 10.7 months. The primary endpoint was spleen volume response rate (SVRR; ≥35% spleen volume decrease from baseline to end of cycle 6 [EOC6]). The SVRR was 31% in the ITT Population and 30% in the Stringent Criteria Cohort. Median duration of spleen volume response was not reached. Symptom response rate (≥50% reduction from baseline to EOC6 in total symptom score [TSS] on the modified Myelofibrosis Symptom Assessment Form [MFSAF]) was 27%. Grade 3-4 anemia and thrombocytopenia rates were 38% and 22%, respectively. Patients with advanced MF substantially pretreated with ruxolitinib attained robust spleen responses and reduced symptom burden with fedratinib.
引用
- Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020. PMID: 32129512. doi:10.1002/ajh.25777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。